Image
illustration
Venture Capital Acquisitions & Partnerships

MIMETAS and Roche enter into a collaboration to develop human disease models for drug development

Tuesday 6 July, 2021
Body

Mimetas and Roche enter into a collaboration to develop human disease models to characterize novel compounds in inflammatory bowel disease (IBD) and hepatitis B virus infections (HBV). 

Mimetas will be responsible for developing tissue-based disease models and assays in the OrganoPlate, its proprietary organ-on-a-chip platform that increases predictability of biomarkers and reduces animal use in scientific testing. Roche will gain access to technology, disease models and scientific results. Roche will also receive an option to exclusively license specific disease models and assays for use in drug discovery.

Content